New biologic therapy for systemic lupus erythematosus


    loading  Checking for direct PDF access through Ovid

Abstract

HighlightsBelimumab is the first approved biologic therapy for SLE.Rituximab appears beneficial in refractory patients.Epratuzumab is showing promise as future biologic therapy.Interferon antagonists and peptide-based therapies are potential future therapies.Systemic lupus erythematosus (SLE) is a heterogenous multi-systemic autoimmune disease that is associated with considerable morbidity and mortality. Rituximab is one of the earliest biologic therapies used in SLE. It performed well in off-label studies but failed to demonstrate efficacy in randomised controlled trials. Abatacept is a biologic developed for inflammatory arthritis but has shown promise in SLE. Belimumab is the first biologically approved therapy in fifty years for treatment of SLE. The development of biological therapies for SLE parallels the increasing understanding of the immunopathogenesis of SLE and looks promising. New drugs in development are those targeting the co-stimulatory modulation, cytokines and the B and T cells. Of interest are epratuzumab, the interferon antagonists and peptide-based therapies.

    loading  Loading Related Articles